Most advice about press releases assumes the hard part is getting an editor to care. In this category the hard part happens earlier, and almost nobody writing a CBD announcement knows it.
Before a journalist ever sees your release, it passes through a compliance review at the distribution service. Major wire services apply extra scrutiny to hemp and CBD announcements, and copy containing health claims gets rejected or sent back for revision. Brands submit, get bounced, assume the wire is hostile to the category, and give up.
The wire is not hostile. It is protecting itself from the same enforcement risk you should be protecting yourself from, and once you understand what it is screening for, clearing it becomes routine.
The wire rejects you before an editor ever reads it
The screening is looking for a specific thing: language suggesting your product treats, prevents, cures or mitigates a condition. That includes the softened versions people think are safe. Supports healthy sleep. Helps with everyday stress. Promotes recovery. Eases discomfort.
Those phrases feel like marketing rather than medicine to the person writing them. They read differently to a regulator. The FTC has brought enforcement actions against CBD companies over unsubstantiated health claims, including a 2020 sweep it called Operation CBDeception, and the FDA has issued warning letters on the same basis for years. The wire services know this history, and they screen accordingly.
So the first rule for any press release for CBD brands is subtraction. Take your draft, highlight every word describing what the product does to a person, and delete all of it. What remains will feel thin. That thinness is the problem you now have to solve with an actual news hook, which is the work you were avoiding by leaning on effect language in the first place.
A release that says nothing about effects and nothing newsworthy is a nothing release. A release that says nothing about effects and announces a genuine business development gets distributed and sometimes gets picked up.
Write for two readers at once
Every release in this category has two readers, and they want opposite things.
The compliance reviewer wants claims removed, qualifiers present, and nothing that implies a medical outcome. Satisfying that reader alone produces a document so cautious it is unreadable.
The editor wants a reason to care, expressed in the first sentence, with a number or a name in it. Satisfying that reader alone gets you rejected before the editor exists.
The Two-Reader Rule is the discipline of writing one document that passes both. In practice it means your news has to live in verifiable business facts rather than in product benefits. Funding. Distribution. Testing. Manufacturing. Regulation. Litigation. Leadership. Those are all things you can state plainly, that no compliance reviewer will flag, and that a business editor can publish.
The brands that struggle here are the ones whose only news is that their product is good. That is not a claim you can make in this category, which is inconvenient and also clarifying: it forces you to develop actual news.
Five angles that clear both readers
The first angle is testing and transparency. You have moved to per-batch published results, added a contaminant screen, switched to an ISO-accredited lab, or begun publishing potency data as readable text rather than scanned PDFs. In a category with a documented mislabeling history, a brand raising its own verification standard is a legitimate business story, and trade press covers it.
The second angle is distribution and retail. A new retail partner, entry into a new state, a chain listing, an international shipment. This is the most-published type of release in every consumer category because it is concrete, dated and checkable. It clears compliance trivially because it contains no claims at all.
The third angle is funding, ownership or expansion. A raise, an acquisition, a new facility, a hiring round with a number attached. Business desks and trade publications run these consistently. Include the figures you are permitted to disclose, because a funding release without an amount rarely gets picked up.
The fourth angle is regulatory and policy. You responded to a rule change, adapted to a new state framework, joined an industry standards body, or have a position on pending legislation. This angle is under-used and disproportionately valuable, because reporters covering hemp policy need operators willing to speak and most brands stay silent.
The fifth angle is supply chain and agriculture. A new growing partner, a shift in extraction method, a domestic sourcing change, a sustainability measure with a measurable outcome. Agriculture and manufacturing reporters cover this, and it moves you out of the crowded wellness lane into a beat with far less competition.
Five angles, none of which mention what the product does to anybody.
The structure, line by line
Headline. One line, under about eighty characters, stating the business fact. Company name, verb, object. No adjectives about the product. “Riverbend Hemp Adds Per-Batch Potency Testing Across Full Product Line” works. “Riverbend Hemp Launches Revolutionary New Wellness Range” fails both readers at once.
Dateline and first paragraph. City, date, then the news in a single sentence containing who, what and when. If an editor reads only this sentence, they should know whether the story is for them. Put the number here if you have one.
Second paragraph. The context that makes the fact matter. Market conditions, the regulatory backdrop, what changed in the category. This is where you explain why a reader should care without claiming anything about your product.
Third paragraph. The quote. One quote, from a named executive, containing something a person would actually say. Quotes are where health claims sneak back in, because founders want to talk about how the product helps people. Keep the quote on the business fact. A quote about why you invested in better testing is publishable. A quote about how your tincture helps customers unwind is not.
Fourth paragraph. Supporting specifics. Lab name, states, dates, volumes, partner names. This is the paragraph a reporter mines for detail, and its thinness is the usual reason a release gets ignored.
Boilerplate. Three or four sentences on the company: founding year, location, what you make, where it is sold. Describe the product category factually. Do not describe benefits.
Contact. A name, a direct email and a phone number that a person answers. Not a generic inbox.
Length, somewhere between four hundred and five hundred words. Longer gets skimmed, shorter reads as unfinished.
Where to send it
Wire distribution and direct pitching do different jobs, and brands in this category usually need both.
The wire gives you a citable, dated, permanent record of the announcement. That matters more than the pickup it generates, because a wire release becomes a source that retailers, partners and AI answer engines can find and reference later when they are assessing whether your brand is real. Budget it as documentation rather than as publicity.
Direct pitching is where actual coverage comes from. Build a short list of hemp and supplement trade publications, business reporters in your home state, and the agriculture or manufacturing desks relevant to your supply chain angle. Send the release as the body of an email rather than an attachment, with two sentences above it explaining why this reporter specifically.
Expect the trade press to respond first, the local business press second, and consumer media rarely and only on the funding or regulatory angles.
One last point that most brands miss. Every release you publish becomes part of the record that systems read when someone asks whether your brand is credible. A trail of factual, dated, business-focused announcements reads as a real company. A trail of wellness copy reads as marketing and gets discounted.
So look at your last three releases. If every one of them was about a product launch, what exactly have you given anyone to verify?